Novartis AG has declined a $100 million option to extend its landmark partnership with Alnylam Pharmaceuticals Inc. for the development of new RNAi therapeutics, a deal once valued at up to $700 million. (BioWorld Today)

Roche AG and reMYND will join forces to develop two classes of compounds against Parkinson's disease and Alzheimer's disease. The total deal is worth as much as $637 million to reMYND as milestones are met. (BioWorld International)